Aminopyrrolidines as chemokine receptor antagonists
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to novel aminopyrrolidines of formula I
pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
-
Citations
17 Claims
- 1. A compound of formula I
- 14. A method of treating a CCR2 dependent disease or condition, wherein the CCR2 dependent disease or condition is an autoimmune disease selected from rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), sepsis, psoriasis, psoriatic arthritis, inflammatory bowel disease, Crohn'"'"'s disease, lupus, multiple sclerosis, juvenile chronic arthritis, Lyme arthritis, reactive arthritis, septic arthritis, spondyloarthropathy and systemic lupus erythematosus, comprising administering a therapeutically effective amount of a compound of formula I
-
16. A pharmaceutical composition comprising a compound of formula I
-
17. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of
Specification